Study of the CD40 Agonistic Monoclonal Antibody APX005M

Key Inclusion Criteria:

Histologically documented diagnosis of solid tumor
For subjects in the every 2 week and every 1 week dosing cohorts histologically or cytologically documented diagnosis of urothelial carcinoma, melanoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, or any solid tumor with high microsatellite instability status (MSI-high)
No known effective therapy options are available
Measurable disease by RECIST 1.1
ECOG performance status of 0 or 1
Adequate bone marrow, liver and kidney function
No toxicities related to prior treatment related toxicities with the exception of alopecia and neuropathy
Negative pregnancy test for women of child bearing potential

Key Exclusion Criteria:

Any history of or current hematologic malignancy
Major surgery or treatment with any other investigational agent within 4 weeks
Uncontrolled diabetes or hypertension
History of arterial thromboembolic event
History of congestive heart failure, symptomatic ischemia, conduction abnormalities uncontrolled by conventional intervention, or myocardial infarction
Active known clinically serious infections